Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Istanbul Medipol University Hospital
Henan Cancer Hospital
Hoffmann-La Roche
Shanxi Province Cancer Hospital
NeoImmuneTech
Jazz Pharmaceuticals
Peking University Cancer Hospital & Institute
SN BioScience